Prime Medicine director granted 75,000 stock options
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036.
The 75,000 options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, subject to Foster-Cheek’s continuous service. Following this grant, the filing shows holdings of 75,000 derivative securities, with no open‑market buys or sells reported.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Foster-Cheek Kaye I
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 75,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Key Figures
Option grant size: 75,000 options
Exercise price: $3.06 per share
Option expiration: June 5, 2036
+2 more
5 metrics
Option grant size
75,000 options
Stock Option (right to buy) granted to director on June 5, 2026
Exercise price
$3.06 per share
Conversion or exercise price for the 75,000 stock options
Option expiration
June 5, 2036
Expiration date of the director’s stock option grant
Post‑grant derivative holdings
75,000 derivative securities
Total shares following transaction as reported for the option grant
Vesting date trigger
Earlier of June 5, 2027 or next annual meeting
Full vesting schedule subject to continuous service
Key Terms
Stock Option (right to buy), exercise price, expiration date, derivative securities, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "3.0600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-05T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
derivative securities financial
"derivativeTransactionCount: 1, derivative securities position"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vesting financial
"The shares subject to this option shall vest in full upon the earlier of"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Prime Medicine (PRME) disclose for Kaye I Foster-Cheek?
Prime Medicine disclosed a grant of 75,000 stock options to director Kaye I Foster-Cheek. These options give the right to buy common shares at a fixed price and represent compensation rather than an open‑market stock purchase or sale.
What are the key terms of the 75,000 stock options granted by Prime Medicine (PRME)?
The grant covers 75,000 stock options with an exercise price of $3.06 per share and an expiration date of June 5, 2036. The options allow the director to buy Prime Medicine common stock at that fixed price once vested.
When do the Prime Medicine (PRME) options for Kaye I Foster-Cheek vest?
The 75,000 options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting. Vesting is conditioned on Foster-Cheek’s continuous service to the company through the applicable vesting date.
Did the Prime Medicine (PRME) Form 4 show any stock sales or purchases?
The Form 4 shows a grant of derivative securities, not open‑market trades. It reports the award of 75,000 stock options to a director, with no common stock purchases or sales disclosed in this particular filing.
How many Prime Medicine (PRME) derivative securities does Kaye I Foster-Cheek hold after this grant?
After the reported grant, the filing lists 75,000 derivative securities for Kaye I Foster-Cheek. These represent the newly awarded stock options and reflect her position in this option grant following the transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
